CLChao-Yang Liang

Chao-Yang Liang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Chao-Yang Liang has a total of 42 co-authors. Here are the top co-authors by number of shared publications:

  • Nai-Kang Zhou

    7 shared publications
  • Xi Liu

    Department of Thoracic Surgery The First Medical Center of Chinese PLA General Hospital Beijing People's Republic of China

    6 shared publications
  • Juntang Guo

    The First Medical Center, Department of Thoracic Surgery, Chinese General Hospital of PLA , Beijing 100853

    5 shared publications
  • Xiao-Dong Tian

    Department of Thoracic Surgery, Hainan Hospital of PLA General Hospital, Haitangwan, Sanya

    5 shared publications
  • Tao Zhang

    Department of Thoracic Surgery The First Medical Center of Chinese PLA General Hospital Beijing People's Republic of China

    4 shared publications
  • Yang Liu

    Department of Thoracic Surgery, The First Medical Center, The Chinese PLA General Hospital, Beijing, People’s Republic of China

    4 shared publications

Latest Publications

  • Open Access

    Clinical efficacy and safety of adjuvant EGFR‐TKIs for resected stage IB lung adenocarcinoma: A real‐world study based on propensity score matching

    by Leilei Shen, Juntang Guo, Weidong Zhang, Lianbin Zhang, Xi Liu, Tao Wang, Tao Zhang, Chaoyang Liang, Yang Liu

    Background: Adjuvant therapy for stage IB non‐small cell lung cancer remains debatable. In this real‐world study, we evaluate the efficacy and safety of adjuvant epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) for resected stage IB lung adenocarcinoma.Methods: This real‐world study recruited 249 patients diagnosed with stage IB disease after surgical resection between January 2013 and September 2021. Sixty‐six (26.5%) patients received adjuvant targeted therapy (TKIs group), and 183 (73.5%) were enrolled in the clinical observation (CO) group. Propensity scores were matched to minimize the observed confounder effects between the two groups, and 59 patient pairs were matched. The primary endpoint was disease‐free survival (DFS).Results: In the TKI group, 38 (64.4%) patients chose to receive icotinib, 27.1% (16/59) received gefitinib, and 5 patients (8.5%) chose osimertinib. The median follow‐up time was 30.8 months (range: 7–107 months). Two (3.4%) patients in the TKI group and 10 (16.9%) in the CO group experienced disease relapse. The 3‐year DFS rates were 98.3% in the TKI group and 83.0% in the CO group (HR: 0.10; 95% CI: 0.01–0.78; p = 0.008). DFS differences were found in the entire cohort (p = 0.005) and the matched cohort (p = 0.024) between the two groups. Multivariate analysis showed that adjuvant EGFR‐TKIs was an independent factor for DFS (HR: 0.211; 95% CI: 0.045–0.979; p = 0.047), along with poor cell differentiation (HR: 5.256; 95% CI: 1.648–16.769; p = 0.005), and spread through air spaces (HR: 5.612; 95% CI: 1.137–27.700; p = 0.034). None of the patients discontinued EGFR‐TKIs owing to the low occurrence rate of treatment‐related serious adverse events.Conclusion: Adjuvant EGFR‐TKIs could significantly improve DFS among patients with stage IB lung adenocarcinoma compared with CO, with a safe and tolerable profile.


  • Open Access

    Long-term results of postoperative unsuspected small cell lung cancer on real-world data

    by Juntang Guo, Leilei Shen, Zhipeng Ren, Yang Liu, Chaoyang Liang

    Background: In traditional opinion, solid pulmonary nodule suspected lung cancer should be confirmed by pathology before the operation to exclude small cell lung cancer (SCLC), considering SCLC tends to be aggressive and surgical effect in the management of SCLC remains controversial. The aim of this study was to evaluate the survival result and risk factors of postoperative unsuspected SCLC. Methods: A total of 120 patients with postoperative unsuspected SCLC who were confirmed by pathology and referred to Chinese PLA General Hospital between 2000 and 2021 were retrospectively analyzed (surgery group). Additionally, 120 patients with limited-stage SCLC who underwent chemotherapy and radiotherapy in the same period were enrolled in the chemoradiotherapy group.. Kaplan–Meier method was used to estimate survival; the Log-Rank test was used to compare survival rates between different groups; a COX stepwise regression model was used for multivariate analysis. Results: Among 120 patients in the surgery group, 28 were with central type and other 92 with peripheral type. The median survival (OS) was 44.85 months, and the 5-year survival rate was 46%. The 5-year survival rates for stage I, II, and III were 52.1%, 45.4%, and 27.8%, respectively. The mean disease-free survival time (DFS) was 30.63 ± 4.38 months, and the 5-year DFS rate was 31.5%. In the chemoradiotherapy group, the mean OS was 21.4 ± 4.26 months, and the 5-year survival rate was 28.3%. The 5-year survival rates for clinical stage I, II, and III were 42.5%, 39.8%, and 20.5%, respectively. The mean progression-free survival (PFS) was 10.63 ± 3.6 months. In the surgery group, one-way ANOVA revealed that the gender, symptoms, smoking history, tumor location, and postoperative radiotherapy were not associated with OS (P ≥ 0.05), while age, surgical approach, surgical method, N stage, TNM stage, and vascular tumor thrombus were related to OS (P < 0.05). Multivariate analysis indicated that the N stage was associated with OS (HR = 1.86 P = 0.042). Conclusion: Surgery and adjuvant therapy were found to have encouraging outcomes in postoperative unsuspected SCLC. Patients with stage I, stage II and part of stage IIIA SCLC could benefit from surgery and the standard lobectomy, and systematic lymph node dissection, is also recommended for these patients.


    • 30 December 2020
      • Vol. 40  (12) , 1793-1798

    左侧非小细胞肺癌4L组淋巴结转移的临床病理学特征及危险因素分析

    by Leilei Shen, Tianyang Yun, Juntang Guo, Yang Liu, Chaoyang Liang

    总结分析左侧肺鳞癌和腺癌4L组淋巴结转移的临床病理学特征及4L组淋巴结转移的危险因素。 回顾性纳入2008年1月~2020年4月在解放军总医院第一医学中心胸外科行左侧肺癌切除+4L组淋巴结清扫的患者134例,依据病理学类型不同分为肺鳞癌组(60例)及肺腺癌组(74例),分析两组间围术期临床病理学特征差异,用logistic回归探讨4L组淋巴结转移的危险因素。 所有患者4L组淋巴结转移率16.4%(22/134),两组患者在年龄、性别、吸烟史、新辅助化疗、肿瘤大小、肿瘤位置及类型、脏层胸膜侵犯、Ki-67指数、4L组淋巴结转移及病理分期(Ⅱ期)有统计学差异,肺鳞癌患者4L组淋巴结转移率明显低于肺腺癌。单因素分析显示病理类型(鳞癌/腺癌)、肺膜侵犯、脉管癌栓、肿瘤标志物阳性、第5组淋巴结转移、第6组淋巴结转移、第7组淋巴结转移、第8组淋巴结转移、第9组淋巴结转移及第10组淋巴结转移是4L组淋巴结转移的高危因素,多因素分析发现,病理类型(鳞癌/腺癌)(OR=0.120,P=0.025)、第5组淋巴结转移(OR=18.784,P=0.007)及第10组淋巴结转移(OR=5.233,P=0.044)为4L组淋巴结转移的独立危险因素。 左侧肺癌出现4L组淋巴结转移并不少见,肺腺癌更易出现,在评估周围结构损伤风险较低,且4L组淋巴结转移可能性较大后应当予以清扫。


  • Open Access

    Choice of therapeutic strategies in intrathoracic anastomotic leak following esophagectomy

    by Juntang Guo, Xiangyang Chu, Yang Liu, Naikang Zhou, Yongfu Ma, Chaoyang Liang

    The aim of this study was to analyze our experience with management of intrathoracic anastomotic leak after esophagectomy.


    • 1 October 2014
      • Vol. 52  (10) , 734-8

    [The clinical application value of dual source CT quantification volume imaging to forecast lung cancer patients' postoperative pulmonary function changing: a prospective study].

    by Min Li, Chaoyang Liang, Juntang Guo, Yongfu Ma, Liang Zhou, Pu Yang, Gongzheng Yang, Yang Liu

    To probe the clinical application and value of dual source CT quantification volume imaging to forecast lung cancer patients' postoperative pulmonary function changing. Between June 2012 and June 2013, there were 233 patients (121 male patients and 112 female patients, with a mean age of (53 ± 16) years) who accepted the thoracoscope lobectomy or unilateral holo-lungs pneumonectomy accepted pulmonary function test before and after 3 months of the surgery. CT scan was conducted at both inspiration phase and expiration phase before the surgery and the lung volume of the single lobe, the pixel exponential distribution histogram, and the average lung density were measured after CT scan. The discrepancy and correlation between the preoperative lung volume accepted by CT and preoperative, postoperative pulmonary function index were compared. The CT volume scan showed that average lung density of the superior part at decubitus position is -(870 ± 22) HU, the inferior part was -(767 ± 16) HU (t = 3.13, P < 0.01). The volume ratio of the right upper lobe, right middle lobe, right lower lobe, left upper lobe, left lower lobe were 20.5%, 10.3%, 23.1%, 24.6%, 21.5%, whole-right lung was 53.9% and whole-left was 46.1%. There were high correlation between CT volume index and preoperative routine pulmonary function index such as total lung capacity, forced vital capacity (FVC), forced expiratory volume in the first second (FEV(1)), residual volume, and FEV(1)/FVC. The highest correlation coefficient were 0.92, 0.76, 0.70, 0.85, 0.56 (t = 3.14, 3.05, 2.86, 3.09, 2.68; all P < 0.01). The highest correlation coefficient for the postoperative pulmonary function index were 0.87, 0.68, 0.75, 0.81, -0.64 (t = 3.10, 2.85, 3.05, 3.02, 2.79; all P < 0.01). It is feasible to use dual source CT quantification volume imaging to predict lung cancer patients' postoperative pulmonary function alteration, which can provide precise predictive value of these patients. CT quantification volume imaging technology has important clinical application value.

    • 1 October 2011
      • Vol. 124  (20) , 3244-8

    Utility of squamous cell carcinoma antigen, carcinoembryonic antigen, Cyfra 21-1 and neuron specific enolase in lung cancer diagnosis: a prospective study from China.

    by Wei-An Song, Xi Liu, Xiao-Dong Tian, Wei Wang, Chao-Yang Liang, Tao Zhang, Jun-Tang Guo, Yang-Hong Peng, Nai-Kang Zhou

    Early detection and diagnosis is urgent for the sake of effective treatment strategy for lung cancer. However, a convenient, economical and relatively precise method is not available. We here report a prospective study to find the possible value of the combined use of four popular tumor markers in the early diagnosis of lung cancer among patients with suspicious nodules in the lung. Six hundred and sixty inpatients with suspicious nodules in the lung were divided into a lung cancer group and a benign pulmonary tumor group according to post-operative histological examinations. Serum levels of four tumor markers including squamous cell carcinoma antigen (SCC), carcinoembryonic antigen (CEA), Cyfra 21-1 and neuron specific enolase (NSE) were assayed for each patient. Receiver operating characteristic (ROC) curves were constructed for each tumor marker. The power of lung cancer diagnosis of each tumor marker, as well as a combination of them were analyzed and compared. The serum levels (median, range) of SCC, CEA, Cyfra 21-1 and NSE were 0.44 (0.01 - 35.70) ng/ml, 2.49 (0.30 - 26.78) ng/ml, 2.30 (0.82 - 73.33) ng/ml and 10.54 (0.10 - 56.41) ng/ml respectively in lung cancer group, and were 0.32 (0.01 - 0.90) ng/ml, 1.60 (0.20 - 8.93) ng/ml, 1.41 (0.72 - 4.82) ng/ml and 9.36 (6.56 - 24.24) ng/ml respectively in the benign pulmonary tumor group. The difference in each tumor marker between the two groups was significant (P < 0.05). The ROCs of SCC, CEA, Cyfra 21-1 and NSE were 0.702 (95%CI, 0.654 - 0.751), 0.611 (95%CI, 0.563 - 0.659), 0.650 (95%CI, 0.601 - 0.700) and 0.598 (95%CI, 0.542 - 0.654) respectively, indicating very low power of these four tumor markers. When a combination of SCC, CEA, Cyfra 21-1 and NSE were employed, the diagnosis power was strengthened. SCC, CEA, Cyfra 21-1 and NSE are valuable in the early diagnosis of lung cancer among suspicious nodules in the lung, especially when they were assayed together for one patient.


    • 1 September 2010
      • Vol. 123  (17) , 2400-4

    Effects and mechanisms of non-restrictive external stent for prevention of vein graft restenosis in a rabbit model.

    by Xiao-Dong Tian, Nai-Kang Zhou, Bo-Jun Li, Cang-Song Xiao, Xi Liu, Chao-Yang Liang, Tao Zhang, Chang-Qing Gao

    Among various treatments preventing vein graft restenosis, external stent is receiving more and more attention. This study aimed to investigate the effect of non-restrictive external stent on the prevention of vein graft restenosis and the potential mechanisms of platelet-derived growth factor (PDGF) in the process of restenosis. Thirty-six "New Zealand white rabbits" were randomly divided into two groups, stented group (group S) and control group (non-stented group, group NS). Each rabbit underwent a reversed autologous external jugular vein into common carotid artery bypass grafting. In group S, the vein grafts were surrounded by a non restrictive stent which was 6 mm in diameter (a kind of Dacron vascular prosthesis); and in group NS, there was no stent to support the vein grafts. The grafts were harvested at the first week (1W), second week (2W) and fourth week (4W) after surgery respectively. The dimensions (including the thickness and area of the intima and media, luminal area) were measured by computer-aided image analysis system, and the intimal hyperplasia ratio was defined as the percentage of the area enclosed by the internal elastic lamina occupied by the intima. At 1W, the difference of the thickness and area of the intima between groups S and NS was not significant (P > 0.05); at 2W and 4W, the thickness and area of the intima and the intimal hyperplasia ratio in group S were less significant than those in group NS (P < 0.05); from 1W to 4W, the thickness and area of the media in group S were smaller than those in group NS (P < 0.05). Immunocytochemistry staining of PDGF-B showed that the percentage of positive cells of intima in both two groups was peaked at 2W, and a significantly smaller percentage was detected in group S compared with that in group NS at 2W and 4W (P < 0.05); the percentage of PDGF-B positive cells of media in both two groups was also peaked at 2W, and that in group S was smaller than that in group NS from 1W to 4W (P < 0.05); and the percentage of PDGF-B positive cells of adventitia in group S was peaked at 4W, whereas the percentage of adventitia in group NS peaked at 2W, and the percentage of adventitia in group S was greater than in group NS at 4W (P < 0.05). Non-restrictive external stenting inhibits the hyperplasia of the intima and media of the vein grafts and reduces the thickness and area of the intima and media; Non-restrictive external stenting inhibits the synthesis of PDGF and changes its distribution, and then inhibits the hyperplasia of the intima.


    • 1 February 2010
      • Vol. 32  (2) , 103-6

    [Comparison of the biodistribution and PET imaging with (11)C-PDT and (18)F-FDG in the mouse model of lung adenocarcinoma].

    by Tao Zhang, Nai-Kang Zhou, Jin-Ming Zhang, Chao-Yang Liang, Xi Liu, Xiao-Dong Tian

    The objective of this study was to compare the biodistribution and PET imaging of (11)C-PDT and (18)F-FDG in a mouse model of lung adenocarcinoma, and to evaluate the value of (11)C-PDT as a new tracer for PET imaging of lung cancer. Twenty four lung adenocarcinoma-bearing mice were randomly divided into two groups, 12 each. The mice received (11)C-PDT or (18)F-FDG injection i.v. respectively. The biodistribution of (11)C-PDT or (18)F-FDG in the mice was measured with a well-gamma detector at 60 min after injection. The PET imagings of mice were performed using either of the two tracers. Considerable uptake of the both radioactive tracers in the tumors was observed. The tumor uptake of (11)C-PDT [(0.65 +/- 0.20)%ID/g] was significantly lower than that of (18)F-FDG [(7.44 +/- 1.56)%ID/g, P < 0.01]. In the (11)C-PDT group, the highest uptake was observed in the liver, kidney and blood in a successively declining order, while the highest uptake of (18)F-FDG was seen in a order of heart, tumor and kidneys. The tumor/muscle ratio of (11)C-PDT uptake was relatively high (2.02 +/- 0.56), but still lower than that of (18)F-FDG (2.95 +/- 0.49, P < 0.01). All values of other tumor/organ ratios (T/NT) of (11)C-PDT uptake were < 2. High radioactive uptake was showed in the tumor and abdominal organs on PET images in the tumor-bearing mice injected with (11)C-PDT, and (18)F-FDG uptake was showed in the heart, tumor and abdominal organs. The tumor PET images with (11)C-PDT and (18)F-FDG were all clear. The uptake of (11)C-PDT in lung cancer is higher than that in muscle tissues, and pulmonary cancers can be detected by PET imaging. (11)C-PDT may be a promising PET tracer for lung cancers.